Nektar Therapeutics (NKTR)

NASDAQ: NKTR · Real-Time Price · USD
8.51
-0.10 (-1.16%)
At close: Jun 20, 2025, 4:00 PM
8.77
+0.26 (3.06%)
After-hours: Jun 20, 2025, 7:52 PM EDT
-1.16%
Market Cap 105.58M
Revenue (ttm) 87.25M
Net Income (ttm) -133.04M
Shares Out 12.41M
EPS (ttm) -9.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 371,253
Open 8.39
Previous Close 8.61
Day's Range 8.27 - 8.86
52-Week Range 6.48 - 22.79
Beta 0.56
Analysts Strong Buy
Price Target 73.75 (+766.63%)
Earnings Date Aug 7, 2025

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 3, 1994
Employees 61
Stock Exchange NASDAQ
Ticker Symbol NKTR
Full Company Profile

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price forecast is $73.75, which is an increase of 766.63% from the latest price.

Price Target
$73.75
(766.63% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market...

10 days ago - Seeking Alpha

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

Brand emphasizes absolute transparency and traceability, sourcing single-ingredient food from small artisan producers Brand emphasizes absolute transparency and traceability, sourcing single-ingredien...

11 days ago - GlobeNewsWire

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Inves...

5 weeks ago - PRNewsWire

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Offic...

6 weeks ago - Seeking Alpha

Nektar Therapeutics Reports First Quarter 2025 Financial Results

SAN FRANCISCO , May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securitie...

6 weeks ago - PRNewsWire

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financi...

7 weeks ago - PRNewsWire

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & I...

3 months ago - PRNewsWire

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Bri...

3 months ago - Seeking Alpha

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable sec...

3 months ago - PRNewsWire

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 202...

3 months ago - PRNewsWire

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in pa...

4 months ago - PRNewsWire

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an inter...

4 months ago - PRNewsWire

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

SAN FRANCISCO , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, Fe...

4 months ago - PRNewsWire

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleuk...

4 months ago - PRNewsWire

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

SAN FRANCISCO , Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in pa...

5 months ago - PRNewsWire

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (A...

7 months ago - PRNewsWire

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - SAN FRANCISCO , Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics ...

7 months ago - PRNewsWire

Multiple Catalysts Ahead For Nektar Therapeutics

Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, al...

7 months ago - Seeking Alpha

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

8 months ago - Seeking Alpha

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable secu...

8 months ago - PRNewsWire

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at we...

8 months ago - PRNewsWire

Nektar Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare...

8 months ago - PRNewsWire

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's (REZPEG) differentiated mechanism of action.

8 months ago - Benzinga

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 mill...

8 months ago - PRNewsWire

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-b...

8 months ago - PRNewsWire